Continuing Medical Education
The Duke University School of Medicine designates this educational activity for a maximum of 6.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Content Reviewer:
Kimberly L. Blackwell, MD Duke University
Medical Center
Durham, North Carolina
Who Should Attend
This educational activity is designed for medical oncologists, radiation oncologists, surgical oncologists, pathologists and other healthcare providers involved and/or interested in the diagnosis, treatment, and management of patients with breast cancer.
Objectives
Upon completion of this activity, participants should be able to:
- Evaluate genomic and proteomic tools for the assessment of recurrence risk, prediction of benefit from chemotherapy, and individualization of therapeutic decision making, while identifying the latest and most important prognostic and predictive factors in breast cancer
- Determine where novel agents including PARP inhibitors, anti-angiogenic agents, and novel anti-tubulin agents can be used to create new standards of care for patients with early-stage, locally-advanced or metastatic breast cancer
- Compare and contrast the most appropriate treatment regimens utilizing neoadjuvant and adjuvant therapies including which patient population would benefit most from extended aromatase inhibitor treatment
- Comment on current and emerging research in the pathogenesis and therapies for triple-negative breast cancer and evaluate the potential for improved patient prognosis
- Describe the biologic rationale for HER2-targeted therapies, and discuss recent clinical trial data evaluating novel HER2-directed agents
- Address the current controversies in the management of locally-advanced and metastatic breast cancer including decisions on continued therapy after disease progression
- Assess the appropriate therapeutic response to ductal carcinoma in situ and the appropriate timing of sentinel lymph node biopsy
- Determine the implications of “BRCAness” syndrome to the outcome of women with cancer and how this concept has impacted the development of new therapeutic
Kimberly L. Blackwell, MD
Duke University Medical Center
Durham, North Carolina
Scott D. Christensen, MD
University of California, Davis Cancer
Center
Sacramento, California
Stefan Glück, MD
University of Miami Miller School of Medicine
Miami, Florida
Mohammad Jahanzeb, MD, FACP
Lynn Cancer Institute
Boca Raton, Florida
Paul Marcom, MD
Duke University Medical Center
Durham, North Carolina
Monica Morrow, MD
Memorial Sloan Kettering Cancer Center
New York, New York
Ruth M. O’Regan, MD
Winship Cancer Institute Emory University
Atlanta, Georgia
Christy A. Russell, MD
University of Southern California
Los Angeles, California
Stephen F. Sener, MD
Keck School of Medicine University of Southern California
Los Angeles, California
8:00 am
Welcome and introduction
Ruth M. O’Regan, MD – chairperson
Christy A. Russell, MD – chairperson
Session I: Local control and Neoadjuvant therapy
8:10 am
Pre-session audience survey
8:20 am
Didactic: Results from ACOSOG Z-011: Is auxiliary node dissection required for a positive sentinel node biopsy?
Monica Morrow, MD
8:45 am
Debate: Should all patients undergo MRI screening prior to surgery?
Yes: Stephen F. Sener, MD
No: Monica Morrow, MD
9:10 am
Didactic: DCIS: Local and systemic therapy - a case-based discussion
Stephen F. Sener, MD
Christy A. Russell, MD
9:30 am Debate: What is the appropriate timing of auxiliary sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy?
Before chemo: Stephen F. Sener, MD
After chemo: Monica Morrow, MD
9:55 am
Coffee Break
10:15 am
Didactic: Clinical options for trastuzumab-resistant breast cancers
Mohammad Jahanzeb, MD, FACP
10:35 am
Didactic: “BRCAness” syndrome in women’s cancers
Paul Marcom, MD
10:55 am
Debate: Treatment decisions in patients with N1 ER-positive breast cancer should be based on 21-gene recurrence score
Yes: Ruth M. O’Regan, MD
No: Stefan Glück, MD, PhD
11:20 am
Debate: Should bevacizumab be incorporate into standard treatment regimens for all breast cancer patients?
Yes: Scott D. Christensen, MD
No: Mohammad Jahanzeb, MD, FACP
11:45 am
Post-session audience survey
11:55 am
Lunch served
Session II: Adjuvant therapy and Metastatic disease
1:10 pm
Pre-session audience survey
1:20 pm
Debate: Young and health node-positive breast cancer patients should routinely be treated with anthracycline in combination with taxanes and trastuzumab
Yes: Christy A. Russell, MD
No: Ruth M. O’Regan, MD
1:40 pm
Didactic: Circulating tumor cells: prognostic significance and predictive value in the management of metastatic breast cancer
Stefan Glück, MD, PhD
2:00 pm
Didactic: Appropriate management of small cancers
Kimberly L. Blackwell, MD
2:25 pm
Didactic: Determining the optimal duration of antiangiogenic therapy and use beyond disease progression
Scott D. Christensen, MD
2:45 pm
Coffee Break
3:05 pm
Debate: Triple negative breast cancers should be treated with a platinum
Yes: Kimberly L. Blackwell, MD
No: Paul Marcom, MD
3:30 pm
Debate: Who should have extended AI adjuvant therapy past 5 years?
All patients: Mohammad Jahanzeb, MD, FACP
No one: Ruth M. O’Regan, MD
3:55 pm
Didactic: PARP inhibitors: Under which clinical setting should they be considered?
Stefan Glück, MD, PhD
4:15 pm
Post-session audience survey & closing remarks
4:30 pm
Adjourn
Registration Fees
Regular........................................$150.00
Nurses/Residents/Students*......................$75.00
*proof of eligibility must accompany registration
Registration Procedures
To Register: You may register online by August 19, 2010 at www.imedex.com or by calling Imedex at +1 (678) 242 0906. Registration confirmations will be issued before the meeting.
To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.
Payment: To pre-register, registration and payment must be received no later than August 19, 2010. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.
Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.
Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the agenda.
Cancellation:For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than August 19, 2010. The amount of registration fees remitted, minus a $50 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after August 19, 2010.
Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.
Dear Colleagues,
It is with great pleasure that we invite you to attend the 16th Annual Perspectives in Breast Cancer, a dynamic forum for leaders in breast cancer research and patient care to increase their knowledge and share their challenges and successes in disease management.
This year, we changed the format of the conference to give you, a practicing clinician, with a comprehensive, one day update of didactic presentations in conjunction with lively and instructive debates. Topics include clinical options for trastuzumab-resistant breast cancers, “BRCAness” syndrome in women’s cancers, and appropriate management of small cancers.
Please join us in New York for what promises to be a rewarding professional update.
Sincerely,
Christy A. Russell, MD
Ruth M. O'Regan, MD
Chairs
Organizer
Imedex
11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com
Conference Location and Registration
Westin New York at Times Square
270 West 43rd Street
New York, New York
10036
Tel.: +1 (212) 201 2700
Fax: +1 (212) 201 2701
Web:
www.westinny.com
The Registration and Information Desk will be staffed
August 28, 2010 from 7:00 am – 4:30 pm.
Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.
In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.
©2010 Imedex®, LLC. All rights reserved.
Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.
The following company has provided an educational grant in support of this Conference:
GOLD
Genentech BioOncology
Several options are available to companies interested in supporting this conference.
For more information, please contact Imedex at +1 (770) 751 7332, or by email at cme@imedex.com.
The following companies are exhibiting at this conference:
Opportunities are available to companies interested in exhibiting at this conference.
For more information, please contact Cori Gunter at +1 (678) 242 0712, or by email at c.gunter@imedex.com.
